Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Extends Russian Presence, Inks Second Agreement With ChemRar

This article was originally published in PharmAsia News

Executive Summary

Heeding a government call to support local innovation, Swiss drug maker Roche has stepped up efforts in the fast-growing Russia pharma market, announcing a licensing agreement May 24 with TeaRx Ltd. that will provide the Moscow-based start up with development and commercialization rights for an experimental anti-thrombotic candidate in Russia and 12 other countries
Advertisement

Related Content

Priming Russia’s Pharma Industry For Innovation
A Busy Month: Russia Looks To Localization, Technology Transfer To Spur Innovation (Part 1 of 2)
Russia's First BioPharma Public-Private Partnership Eyes Bio-Betters, Attracts $110 Million
Russia's First BioPharma Public-Private Partnership Eyes Bio-Betters, Attracts $110 million
Pfizer Joins Russia Land Rush, But Chooses To Partner Rather Than Build
Novartis, AstraZeneca Pledge Support For Russia At St. Petersburg Economic Forum In Latest Big Pharma Move To Go Local
Novartis, AstraZeneca Pledge Support For Russia At St. Petersburg Economic Forum In Latest Big Pharma Move To Go Local
Will Innovation Replace Branded Generics As Dominant Strategy For Big Pharma In Emerging Markets? (Part 2 of 2)
Russia Pledges $3.9 Billion For Local Pharma Growth, As Big Pharma Scrambles To Set Up Shop
Russia Pledges $3.9 Billion For Local Pharma Growth, As Big Pharma Scrambles To Set Up Shop
Advertisement
UsernamePublicRestriction

Register

SC078066

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel